INVO Fertility (NASDAQ:IVF) and Minerva Surgical (NASDAQ:UTRS) Head-To-Head Analysis

INVO Fertility (NASDAQ:IVF) and Minerva Surgical (NASDAQ:UTRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Institutional & Insider Ownership

12.0% of INVO Fertility shares are owned by institutional investors. 0.7% of INVO Fertility shares are owned by insiders. Comparatively, 8.5% of Minerva Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for INVO Fertility and Minerva Surgical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1	0	0	0	1.00
Minerva Surgical	0	0	0	0	0.00

Given Minerva Surgical’s higher probable upside, analysts plainly believe Minerva Surgical is more favorable than INVO Fertility.

Profitability

This table compares INVO Fertility and Minerva Surgical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-417.02%	N/A	-92.42%
Minerva Surgical	N/A	N/A	N/A

Valuation and Earnings

This table compares INVO Fertility and Minerva Surgical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.53 million	0.41	-$9.10 million	($630.30)	0.00
Minerva Surgical	$51.69 million	0.00	-$34.11 million	($8.21)	N/A

INVO Fertility has higher earnings, but lower revenue than Minerva Surgical. INVO Fertility is trading at a lower price-to-earnings ratio than Minerva Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

INVO Fertility has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, Minerva Surgical has a beta of 2.85, suggesting that its share price is 185% more volatile than the S&P 500.

Summary

Minerva Surgical beats INVO Fertility on 8 of the 11 factors compared between the two stocks.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.